Literature DB >> 33153672

Inhaled Corticosteroids and Endocrine Effects in Childhood.

David B Allen1.   

Abstract

Asthma is the most common chronic inflammatory disease of children, and inhaled corticosteroids (ICSs) are the most effective and commonly used treatment of persistent asthma. ICSs currently approved for and commonly used by children with asthma include beclomethasone dipropionate, budesonide, fluticasone propionate, mometasone furoate, ciclesonide, and triamcinolone acetonide. This article reviews 4 areas critical to understanding potential adverse endocrine outcomes of ICSs and placing them in proper perspective: (1) influence of drug/delivery device properties on systemic steroid burden; (2) adrenal insufficiency during ICS treatment; (3) growth effects of ICS and asthma itself; and (4) bone mineral accretion during ICS therapy.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adrenal suppression; Growth; Inhaled corticosteroids

Year:  2020        PMID: 33153672     DOI: 10.1016/j.ecl.2020.07.003

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  3 in total

1.  Adverse Drug Events Related to Common Asthma Medications in US Hospitalized Children, 2000-2016.

Authors:  Luyu Xie; Andrew Gelfand; Matthew S Mathew; Folefac D Atem; Nimisha Srikanth; George L Delclos; Sarah E Messiah
Journal:  Drugs Real World Outcomes       Date:  2022-06-08

Review 2.  Doxofylline for Pediatric Asthma Steps 1-4. Pediatric Asthma: New Role for an Old Drug.

Authors:  Vincenzo Fierro; Anna Lucia Piscitelli; Edda Battaglia; Alessandro Fiocchi
Journal:  Front Pediatr       Date:  2022-06-22       Impact factor: 3.569

Review 3.  Pharmacological Strategies and Recent Advancement in Nano-Drug Delivery for Targeting Asthma.

Authors:  Aftab Ahmad
Journal:  Life (Basel)       Date:  2022-04-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.